Table 1.

Baseline characteristics of stage IV patients with colorectal cancer based on TBIL, DBIL, and IBI

Characteristics	Total patients	TBIL (N=154) (μmol/L)		P *	DBIL (N=154) (μmol/L)		P *	IBI (N=154) (μmol/L)		P *
	(N=154)	≦12.9	>12.9		≦6.1	>6.1		≦4.8	>4.8
		(N=98)	(N=56)		(N=119)	(N=35)		(N=42)	(N=112)
Age (y)
≦64	83 (53.9%)	49 (31.8%)	34 (22.1%)	.199	62 (40.3%)	21 (13.6%)	.410	18 (11.7%)	65 (42.2%)	.092
>64	71 (46.1%)	49 (31.8%)	22 (14.3%)		57 (37.0%)	14 (9.1%)		24 (15.6%)	47 (30.5%)
Gender
Male	101 (65.6%)	61 (39.6%)	29 (26.0%)	.249	72 (46.8%)	29 (18.8%)	.014	29 (18.8%)	72 (46.8%)	.580
Female	53 (34.4%)	101 (24.0%)	8 (10.4%)		47 (30.5%)	6 (3.9%)		13 (8.4%)	40 (26.0%)
Tumor site
Rectal	59 (38.3%)	37 (24.0%)	22 (14.3%)	.851	47 (30.5%)	12 (7.8%)	.577	15 (9.7%)	44 (28.6%)	.685
Colon	95 (61.7%)	61 (39.6%)	34 (22.1%)		72 (46.8%)	23 (14.9%)		27 (17.5%)	68 (44.2%)
Operation
No	55 (35.7%)	31 (20.1%)	24 (15.6%)	.162	40 (26.0%)	15 (9.7%)	.316	12 (7.8%)	43 (27.9%)	.257
Yes	99 (64.3%)	67 (43.5%)	2 (20.8%)		79 (51.3%)	20 (13.0%)		30 (19.5%)	69 (44.8%)
Chemo‐radiotherapy
No	39 (25.3%)	24 (15.6%)	15 (9.7%)	.753	31 (20.1%)	8 (5.2%)	.703	11 (7.1%)	28 (18.2%)	.880
Yes	115 (74.7%)	74 (48.1%)	41 (26.6%)		88 (57.1%)	27 (17.5%)		31 (20.1%)	84 (54.5%)
CEA
<5 ng/mL	45 (29.2%)	36 (23.4%)	9 (5.8%)	.007	42 (27.3%)	3 (1.9%)	.002	15 (9.7%)	30 (19.5%)	.278
≥5 ng/mL	109 (70.8%)	114 (40.3%)	12 (30.5%)		77 (50.0%)	32 (20.8%)		27 (17.5%)	43 (53.2%)
CA 19‐9
<37 U/mL	74 (48.1%)	49 (31.8%)	25 (16.2%)	.522	62 (40.3%)	12 (7.8%)	.064	20 (13.0%)	54 (35.1%)	.948
≥37 U/mL	80 (51.9%)	49 (31.8%)	31 (20.1%)		57 (37.0%)	23 (14.9%)		22 (14.3%)	58 (37.7%)

TBIL, total bilirubin; DBIL, direct bilirubin; IBI, indirect bilirubin; CEA, carcinoembryonic antigen; CA19‐9, carbohydrate antigen 19‐9.

The bold represent that P value was statistically significant.

*Difference between groups was tested by Chi‐square test.